Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.

e15120 Background: Clinical trials suggest that combining therapy of transcatheter arterial chemoembolization (TACE) with sorafenib for the treatment of patients with advanced hepatocellular carcinoma (HCC) shows a superior safety and tolerability profile. The present study aimed to retrospectively analyze the utility and prognostic factors of this combined therapy in advanced HCC patients. Methods: Patients with advanced HCC, treated by TACE and sorafenib subsequently, between February 2010 and September 2012 in our hospital, were retrospectively analyzed. After sorafenib treatment for 12 weeks, abdominal enhanced CT or MRI was used to evaluate short-term outcomes and clinical benefit rate (CBR). Overall survival (OS) and adverse events (AEs) were recorded during follow-up. Univariate and multivariate analyses were used to identify relationships between baseline characteristics and OS. Results: A group of 51 patients with advanced HCC were included. Common AEs for sorafenib were hand-foot skin reaction, ...